TCG Crossover Management, LLC — 13F Holdings & Portfolio

CIK 1839948 · latest 13F-HR filed 2026-08-14

TCG Crossover Management, LLC manages $4.16B in 13F-reported U.S. long-equity assets across 54 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are ABVX (19.24%), TNGX (6.82%), CGON (6.27%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 12 new positions and exited 7; 27 existing positions rose in reported value and 11 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$4.16B

Long-equity book

Holdings
54

Distinct positions

Period
2026-06-30

Filed 2026-08-14

Q/Q Activity
+12 / −7 / ↑27 / ↓11

vs 2026-03-31

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q2 26

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q1 26 → Q2 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

4 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 57.4%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

As of the firm’s regulatory filing dated May 29, 2026.

Assets Under Management
$5.06B
Discretionary
$5.06B
Employees
16
Accounts
3
Address
245 LYTTON AVE.
SUITE 350
PALO ALTO, CA 94301
Phone
(650) 924-9424
Name Title / Status Ownership Type
SKALING, CRAIG, DAVID ControlCHIEF OPERATING OFFICER AND CHIEF COMPLIANCE OFFICER
since Feb 2022
Less than 5%Individual
YU, CHEN, MING ControlMANAGING PARTNER
since Oct 2020
75% or moreIndividual
Ownership & leadership changes · 1 filing with changes since Nov 18, 2020

From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.

Mar 31, 2022 filing
  • No longer listedFELIX, JAIME, MORA · CHIEF COMPLIANCE OFFICER AND CHIEF FINANCIAL OFFICER · Less than 5% · control person · listed since Oct 2020
  • AddedSKALING, CRAIG, DAVID · CHIEF OPERATING OFFICER AND CHIEF COMPLIANCE OFFICER · Less than 5% · control person
Nov 18, 2020 filing (earliest on record)
  • ListedFELIX, JAIME, MORA · CHIEF COMPLIANCE OFFICER AND CHIEF FINANCIAL OFFICER · Less than 5% · control person
  • ListedYU, CHEN, MING · MANAGING PARTNER · 75% or more · control person

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

TCG Crossover Management, LLC Holdings (2026-06-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 ABIVAX SA AMERICAN DEPOSITARY SHARES ABVX 00370M103 $800.6M 19.24% 6,007,834 SH
2 TANGO THERAPEUTICS INC TNGX 87583X109 $283.9M 6.82% 9,081,201 SH
3 CG ONCOLOGY INC CGON 156944100 $260.8M 6.27% 3,670,206 SH
4 COGENT BIOSCIENCES INC COGT 19240Q201 $187.9M 4.52% 4,854,436 SH
5 IMMUNOVANT INC IMVT 45258J102 $171.8M 4.13% 4,457,988 SH
6 SPYRE THERAPEUTICS INC SYRE 00773J202 $168.7M 4.06% 1,900,582 SH
7 DIANTHUS THERAPEUTICS INC DNTH 252828108 $163.4M 3.93% 1,676,624 SH
8 MIRUM PHARMACEUTICALS INC MIRM 604749101 $124.3M 2.99% 1,062,049 SH
9 ZAI LAB LTD-ADR ZLAB 98887Q104 $116.6M 2.80% 6,137,627 SH
10 AMYLYX PHARMACEUTICALS INC AMLX 03237H101 $112.1M 2.70% 6,243,812 SH
11 MONTE ROSA THERAPEUTICS INC GLUE 61225M102 $111.9M 2.69% 4,622,151 SH
12 BIOCRYST PHARMACEUTICALS INC BCRX 09058V103 $110.2M 2.65% 11,020,968 SH
13 VOR BIOPHARMA INC VOR 929033207 $104.4M 2.51% 5,673,078 SH
14 TYRA BIOSCIENCES INC TYRA 90240B106 $103.8M 2.49% 3,248,980 SH
15 DYNE THERAPEUTICS INC DYN 26818M108 $102.5M 2.46% 4,615,144 SH
16 DISC MEDICINE INC IRON 254604101 $98.1M 2.36% 1,341,862 SH
17 RELAY THERAPEUTICS INC RLAY 75943R102 $80.0M 1.92% 4,273,356 SH
18 SAVARA INC SVRA 805111101 $76.2M 1.83% 12,362,205 SH
19 AURA BIOSCIENCES INC AURA 05153U107 $67.7M 1.63% 9,533,333 SH
20 REVOLUTION MEDICINES INC RVMD 76155X100 $63.8M 1.53% 340,899 SH
21 FIRST TRACKS BIOTHERAPEUTICS TRAX 337185102 $58.3M 1.40% 2,895,304 SH
22 KODIAK SCIENCES INC KOD 50015M109 $56.3M 1.35% 1,445,538 SH
23 AVALO THERAPEUTICS INC AVTX 05338F306 $55.8M 1.34% 3,017,120 SH
24 LB PHARMACEUTICALS INC LBRX 50180M108 $47.0M 1.13% 1,447,310 SH
25 CENTURY THERAPEUTICS INC IPSC 15673T100 $43.4M 1.04% 17,754,430 SH
26 TECTONIC THERAPEUTIC INC TECX 878972108 $41.4M 1.00% 1,204,891 SH
27 XENCOR INC XNCR 98401F105 $39.5M 0.95% 2,452,138 SH
28 SURROZEN INC SRZN 86889P208 $38.2M 0.92% 1,473,101 SH
29 EDITAS MEDICINE INC EDIT 28106W103 $36.0M 0.87% 11,111,111 SH
30 MBX BIOSCIENCES INC MBX 55287L101 $35.9M 0.86% 650,000 SH
31 PHARVARIS BV PHVS N69605108 $34.9M 0.84% 1,008,229 SH
32 SILENCE THERAPEUTICS PLC SLN 82686Q101 $33.3M 0.80% 3,033,560 SH
33 INFLARX N V IFRX N44821101 $32.5M 0.78% 14,500,000 SH
34 ALTIMMUNE INC ALT 02155H200 $30.4M 0.73% 10,000,000 SH
35 JANUX THERAPEUTICS INC JANX 47103J105 $27.5M 0.66% 1,789,617 SH
36 PERSPECTIVE THERAPEUTICS INC CATX 46489V302 $27.0M 0.65% 7,915,567 SH
37 AGOMAB THERAPEUTICS NV AGMB 00860C102 $26.7M 0.64% 2,053,233 SH
38 BIOHAVEN LTD BHVN G1110E107 $26.5M 0.64% 1,779,952 SH
39 AKTIS ONCOLOGY INC AKTS 01021M104 $22.5M 0.54% 696,560 SH
40 ALECTOR INC ALEC 014442107 $20.1M 0.48% 10,000,000 SH
41 FORTE BIOSCIENCES INC FBRX 34962G208 $19.6M 0.47% 920,000 SH
42 MONOPAR THERAPEUTICS INC MNPR 61023L207 $18.8M 0.45% 203,327 SH
43 OCULAR THERAPEUTIX INC OCUL 67576A100 $16.2M 0.39% 1,647,752 SH
44 ADC THERAPEUTICS SA ADCT H0036K147 $12.2M 0.29% 11,390,175 SH
45 ALX ONCOLOGY HOLDINGS INC ALXO 00166B105 $11.7M 0.28% 5,655,487 SH
46 ENTRADA THERAPEUTICS INC TRDA 29384C108 $7.8M 0.19% 1,060,230 SH
47 CULLINAN THERAPEUTICS INC CGEM 230031106 $7.4M 0.18% 406,786 SH
48 ARVINAS HOLDING CO LLC ARVN 04335A105 $5.9M 0.14% 707,098 SH
49 KORRO BIO INC KRRO 500946108 $5.5M 0.13% 416,301 SH
50 RESEARCH ALLIANCE CORP CL A RACC G75226103 $5.3M 0.13% 500,000 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-14 $4.16B 54 0001214659-26-010290
2026-03-31 2026-05-15 $3.50B 49 0001214659-26-006367
2025-12-31 2026-02-17 $3.02B 43 0001214659-26-001871
2025-09-30 2025-11-17 $2.03B 40 0001214659-25-016751
Filer Information
Address
245 LYTTON AVE., SUITE 350
PALO ALTO, CA 94301
Phone
(650) 924-9424
Filing Manager
TCG Crossover Management, LLC
PALO ALTO, CA
Signatory
Casey Cwynar
CCO